Selepressin, a novel selective vasopressin V_1A agonist, is an effective substitute for norepinephrine in a phase IIa randomized, placebo-controlled trial in septic shock patients.

ABSTRACT:

Background

Vasopressin is widely used for vasopressor support in septic shock patients, but experimental evidence suggests that selective V_1A agonists are superior. The initial pharmacodynamic effects, pharmacokinetics, and safety of selepressin, a novel V_1A-selective vasopressin analogue, was examined in a phase IIa trial in septic shock patients.

Methods

This was a randomized, double-blind, placebo-controlled multicenter trial in 53 patients in early septic shock (aged ≥18 years, fluid resuscitation, requiring vasopressor support) who received selepressin 1.25 ng/kg/minute (n = 10), 2.5 ng/kg/minute (n = 19), 3.75 ng/kg/minute (n = 2), or placebo (n = 21) until shock resolution or a maximum of 7 days. If mean arterial pressure (MAP) ≥65 mmHg was not m

SUBMITTER: Russell JA 

PROVIDER: S-EPMC5557574 | biostudies-literature | 2017 Aug

REPOSITORIES: biostudies-literature